A very low HR in OS is indeed a tough task for a cancer drug; however, some cancer drugs have been approved based on a (non-OS) primary endpoint with HR<0.4.
I agree. Today, OS HR<0.7 is indeed very good. Any cancer drug with OS HR<0.5 over the present standard of care is a major breakthrough treatment advance.
Market Data 
Markets 
AI
